Short answer
Niagen Bioscience, Inc. (NAGE) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.2). Q2 2026 earnings announcement for quarter ended June 30, 2026.
Niagen Bioscience, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 earnings announcement for quarter ended June 30, 2026
- Exhibit 99.1 contains the financial results and management commentary
- Market focus: operating performance, growth trends, and outlook disclosed in the attached release
Item 7.01 · Regulation FD Disclosure
- Corporate presentation released August 4, 2026 under Regulation FD
- Investor-relevant details are contained in Exhibit 99.2
- Presentation availability may update the company’s strategy, pipeline, or outlook disclosed to investors
Item EX-99.1 · Exhibit EX-99.2
- Q2 sales $29.8M, down from $31.1M; Tru Niagen contributed $24.2M while direct-to-consumer sales grew 23% year-over-year
- Gross margin 64.8%; operating income fell to $0.7M from $3.2M as operating expenses increased to $18.6M
- Net income $1.0M versus $3.6M; adjusted EBITDA $3.0M versus $5.0M, signaling weaker underlying profitability
- Cash from operations $1.6M year-to-date and cash $66.7M; $2.8M stock repurchase during the quarter
- NB4168 received FDA Rare Pediatric Disease and EMA Orphan Medicinal Product designations, adding long-term pharmaceutical optionality with preclinical studies planned for Q3 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Niagen Bioscience, Inc. 8-K filings
Get the next NAGE 8-K as it lands
Follow NAGE for push alerts, or ask the research agent what this filing means.